Comprehensive bloodwork + physician evaluation — only $99 to get started. Check your levels →
Menopause is defined as the point when a woman has gone 12 consecutive months without a menstrual period. But the hormonal changes that drive menopause symptoms begin years earlier — during a transitional phase called perimenopause.
During perimenopause, the ovaries gradually reduce their production of three key hormones:
The decline is not linear. During perimenopause, estrogen and progesterone levels fluctuate dramatically — sometimes spiking, sometimes plummeting — before settling into the consistently low levels of postmenopause. This hormonal volatility is what drives the most intense symptoms.
Understanding which hormone deficiency drives which symptom helps explain why treatment needs to be individualized.
Most women in menopause have deficiencies in all three hormones to varying degrees. This is why effective treatment typically involves a combination approach — not just estrogen alone.
Bioidentical hormone therapy uses hormones that are molecularly identical to what your body produces. For menopause, a typical BHRT protocol may include:
The specific combination, dosing, and delivery methods are determined by your lab results, symptoms, and clinical goals. There is no one-size-fits-all menopause protocol.
For a detailed comparison of bioidentical vs. conventional approaches, see BHRT vs Traditional HRT.
Conventional HRT typically uses conjugated equine estrogens (Premarin) and medroxyprogesterone acetate (Provera) — hormones with molecular structures that differ from human hormones. While effective for symptom relief, these products carry different safety profiles than bioidentical hormones, particularly regarding breast cancer risk and cardiovascular effects.
For a molecular-level comparison, read Bioidentical Hormones vs Synthetic.
Some women are not candidates for hormone therapy or prefer non-hormonal approaches. Options include SSRIs/SNRIs for hot flashes, gabapentin for vasomotor symptoms, vaginal moisturizers and lubricants for dryness, and lifestyle modifications. However, these approaches address individual symptoms rather than the underlying hormonal deficiency — they don’t restore what the body is missing.
Safety is the central concern for most women considering hormone therapy, largely because of the Women’s Health Initiative (WHI) findings published in 2002. Here’s what the evidence shows when we look beyond the WHI headlines:
The KEEPS and ELITE trials demonstrated that starting hormone therapy within 6–10 years of menopause onset is associated with cardiovascular benefit or neutrality. Starting more than 10 years after menopause may carry different risks. This “window of opportunity” is now widely accepted in clinical practice.
Most women seeking hormone therapy are within this window — they’re in their late forties or fifties, experiencing active symptoms that prompted them to seek help.
The E3N French Cohort Study (80,000+ women) found that estradiol combined with micronized progesterone was not associated with increased breast cancer risk — while estrogen combined with synthetic progestins was. This distinction between progesterone and progestins is one of the most important findings in menopause medicine.
Transdermal estradiol avoids the clotting risks associated with oral estrogens, making it the preferred delivery route for most BHRT protocols.
For a complete safety analysis, see Is BHRT Safe? What the Research Says.
The safety conversation is incomplete without acknowledging what happens when menopause symptoms go untreated:
These are not trivial consequences. For many women, the risk of untreated hormonal deficiency outweighs the risks of properly supervised hormone therapy.
Your provider orders a detailed hormone panel that goes beyond what most gynecologists test. This includes estradiol, progesterone, total and free testosterone, DHEA-S, SHBG, thyroid markers (TSH, Free T3, Free T4), cortisol, metabolic markers, and more.
At BHRT Boost, comprehensive lab review is the foundation of every protocol. Your provider reads your labs using optimal reference ranges — not just the broad “normal” ranges that miss subclinical deficiencies.
Your provider reviews your labs alongside your symptom history, medical history, family history, current medications, and personal goals. Together, you develop a protocol that addresses your specific deficiencies.
This is where the individualization happens. A woman with predominantly vasomotor symptoms (hot flashes, night sweats) needs a different protocol than one whose primary complaints are sleep disruption and anxiety. A woman with a history of breast cancer in her family may warrant different monitoring than one without. Your protocol reflects your biology, not an algorithm.
You begin your personalized hormone protocol. Your provider educates you on proper use, timing, and what to expect during the initial adjustment period.
Common starting protocols include:
Your first follow-up typically occurs 6–8 weeks after starting therapy. Labs are redrawn to assess your response, and your protocol is adjusted based on the data. This iterative process continues until your levels are optimized and your symptoms are resolved.
Hormone therapy is a long-term commitment, not a temporary intervention. Regular labs (every 3–6 months initially, then annually once stable) ensure your protocol continues to serve you as your body changes over time.
Weeks 1–2: Sleep often improves first — micronized progesterone’s conversion to allopregnanolone promotes deeper, more restorative sleep. Anxiety and inner restlessness may begin to ease.
Weeks 2–4: Hot flashes and night sweats begin to reduce in frequency and intensity. Energy starts to improve. Mood stabilizes.
Weeks 4–8: Most vasomotor symptoms are significantly improved or resolved. Cognitive clarity returns — brain fog lifts. Libido may begin to improve (testosterone effects build more slowly).
Months 2–4: Body composition changes become noticeable — reduced abdominal fat, improved muscle tone. Skin hydration and elasticity improve. Sexual function continues to improve.
Months 4–6+: Full optimization. Vaginal tissue health improves with sustained estrogen therapy. Bone density stabilization. Patients typically report feeling like themselves again — or better than they’ve felt in years.
Hormone therapy works best as part of a comprehensive wellness strategy:
Not all providers approach menopause the same way. When evaluating a provider for hormone therapy, consider:
At BHRT Boost, every menopause protocol is designed and monitored by providers with deep expertise in hormone optimization, including Dr. Bruce Stratt, who has treated thousands of women through perimenopause and menopause over his career.
Menopause is a natural biological transition — but the symptoms it produces are not something you need to endure without relief. Hormone therapy, when done right, can restore the vitality, clarity, sleep, and quality of life that hormonal decline takes away.
The first step is knowing where you stand. A comprehensive lab panel gives you the data, and a qualified provider gives you the plan.
BHRT Boost Clinical Team
Our clinical team combines decades of experience in hormone optimization, functional medicine, and patient-centered care. Every article is reviewed for medical accuracy and practical relevance.
A clinical comparison of bioidentical hormone replacement therapy (BHRT) and conventional HRT — molecular differences, safety profiles, customization, and how to choose the right approach.
An evidence-based comparison of bioidentical and synthetic hormones — molecular differences, how the body metabolizes each, safety evidence, and why the distinction matters for your treatment.
An evidence-based look at the safety of bioidentical hormone therapy — what the clinical trials show, how BHRT differs from conventional HRT in safety data, and why proper medical oversight matters.
Get started with comprehensive lab testing and a physician evaluation by Dr. Bruce J. Stratt, MD — telehealth or in-person. Initial bloodwork only $99.
